Close

Farmacos Covid19

Clinical management of COVID-19: Living guideline, 15 September 2022

The WHO COVID-19 Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is important. The latest version of this living guideline is available in pdf format (via the ‘Download’ […]

Read More

Two-Year Health Outcomes in Hospitalized COVID-19 Survivors in China

Question  What are the 2-year health outcomes among patients hospitalized for COVID-19 in China? Findings  In this longitudinal cohort study that included 1864 patients, the most common symptoms at 2 years after SARS-CoV-2 infection were fatigue, chest tightness, anxiety, dyspnea, and myalgia, and most symptoms resolved from 1-year to 2-year follow-up, although […]

Read More

New Data on Heterologous COVID-19 Vaccine Combinations

Switching to a different COVID-19 vaccine after a first dose of the Sputnik V C1, ChAdOx1-S, or BBIBP-CorV vaccines can greatly increase immune response while maintaining safety, according to a study published in Cell Reports Medicine. The results provide information for mixing vaccine types in both primary vaccination and vaccine booster schedules, which […]

Read More

Public Health Leaders End Weekly Testing Requirements for Workers

SACRAMENTO – To better align state COVID-19 guidance with the most current federal recommendations, the California Department of Public Health (CDPH) is ending COVID-19 policies that required weekly COVID-19 testing for unvaccinated individuals in high-risk workplaces and schools. Health care facilities, other congregate settings and schools will no longer be […]

Read More

Opinión positiva del CHMP de la EMA a las vacunas bivariantes con BA.4 y BA.5 de Pfizer/BioNTech

El Comité de Medicamentos de Uso Humano de la Agencia Europea del Medicamento, CHMP, ha recomendado autorizar una vacuna bivariante adaptada a las subvariantes BA.4 y BA.5, que contiene, además, la cepa ancestral del SARS-CoV-2. El preparado vacunal ha sido elaborado por Pfizer/BioNTech para personas de doce o más años, con […]

Read More

Paxlovid Reduces Risk of COVID Death by 79% in Older Adults: Study

The antiviral drug Paxlovid appears to reduce the risk of dying from COVID-19 by 79% and decrease hospitalizations by 73% in at-risk patients who are ages 65 and older, according to a new study published in The New England Journal of Medicine. The pill, which is a combination of the drugs nirmatrelvir and ritonavir, […]

Read More

Paxlovid Expiration Dates Extended

Expiration dates have been extended from 9 months after manufacture to 12 months for 4 lots of the COVID-19 antiviral therapy Paxlovid, which consists of copackaged nirmatrelvir tablets and ritonavir tablets. The lot numbers and original expiration dates are listed on the FDA website. The nirmatrelvir-ritonavir lots were manufactured before the FDA […]

Read More

Modeling the Impact of Sexual Networks in the Transmission of Monkeypox virus Among Gay, Bisexual, and Other Men Who Have Sex With Men — United States, 2022

Summary What is already known about this topic? The 2022 monkeypox outbreak is associated with sexual and intimate contact. Survey data suggest that gay, bisexual, and other men who have sex with men (MSM), who have been disproportionately affected, are reducing one-time partnerships. What is added by this report? Modeling […]

Read More
Translate »